Skip to main content
Article
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
The Lancet (2018)
  • Désirée van der Heijde, Leiden University
  • James Cheng-Chung Wei, Chung Shan Medical University
  • Maxime Dougados
  • Philip Mease, University of Washington
  • Atul Deodhar, Oregon Health & Science University
  • Walter P Maksymowych, University of Alberta
  • Filip Van den Bosch, Ghent University Hospital
  • Joachim Sieper, Charité
  • Tetsuya Tomita, Osaka University
  • Robert Landewé
  • Fangyi Zhao, Eli Lilly and Company
  • Eswar Krishnan, Eli Lilly and Company
  • David H. Adams, Eli Lilly and Company
  • Beth Pangallo, Eli Lilly and Company
  • Hilde Carlier, Eli Lilly and Company
  • Melvin Churchill
  • Kathleen Flint
  • Geoffrey Gladstein
  • Maria Greenwald
  • Mary Howell
  • Akgun Ince
  • Jeffrey Kaine
  • Daksha Mehta
  • Eric Peters
  • Roel Querubin
  • John Reveille
  • Richard Roseff
  • Roger Diegel
  • Christine Thai
  • Louis Bessette
  • Frederic Morin
  • Proton Rahman
  • Aaron Alejandro Barrera Rodriguez
  • Fidencio Cons-Molina
  • Sergio Duran Barragan
  • Cassandra Skinner
  • Cesar Pacheco Tena
  • Cesar Ramos Remus
  • Juan Cruz Rizo Rodriguez
  • Seung-Jae Hong
  • Yeon-Ah Lee
  • Ji Hyeon Ju
  • Seong Wook Kang
  • Tae-Hwan Kim
  • Chang Keun Lee
  • Eun Bong Lee
  • Sang Heon Lee
  • Min-Chan Park
  • Kichul Shin
Publication Date
December 1, 2018
DOI
10.1016/S0140-6736(18)31946-9
Citation Information
Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, Philip Mease, et al.. "Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial" The Lancet Vol. 392 Iss. 10163 (2018) p. 2441 - 2451
Available at: http://works.bepress.com/philip-mease/322/